

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7021551

| | |
|------------------------------|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | CORRECTION BY DECLARATION TO CORRECT THE 10 ERRONEOUSLY NULLIFIED PROPERTIES ON COVER SHEET AT REEL 057970 FRAME 0475. ASSIGNOR HEREBY CONFIRMS THAT THE 10 PROPERTIES LISTED THERE AND HEREIN SHOULD NOT HAVE BEEN NULLIFIED. |

CONVEYING PARTY DATA

| Name | Execution Date |
|-----------------------------|----------------|
| AKORN OPERATING COMPANY LLC | 11/12/2021 |

RECEIVING PARTY DATA

| | |
|--------------------------|-----------------------|
| Name: | MEDTECH PRODUCTS INC. |
| Street Address: | 660 WHITE PLAINS ROAD |
| Internal Address: | SUITE 250 |
| City: | TARRYTOWN |
| State/Country: | NEW YORK |
| Postal Code: | 10591 |

PROPERTY NUMBERS Total: 10

| Property Type | Number |
|---------------------|----------|
| Application Number: | 16997148 |
| Application Number: | 17211952 |
| Patent Number: | 8231912 |
| Application Number: | 14722252 |
| Patent Number: | 8449928 |
| Patent Number: | 8932653 |
| Patent Number: | 9050288 |
| Patent Number: | 8900643 |
| Patent Number: | 9301988 |
| Patent Number: | 8535736 |

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: steve.trubac@bcplaw.com

Correspondent Name: STEVE TRUBAC

Address Line 1: 161 NORTH CLARK, SUITE 4300

PATENT

Address Line 4: CHICAGO, ILLINOIS 60601

| | |
|-------------------------|--------------------|
| ATTORNEY DOCKET NUMBER: | 1070900.4 |
| NAME OF SUBMITTER: | STEVEN G. TRUBAC |
| SIGNATURE: | /Steven G. Trubac/ |
| DATE SIGNED: | 11/12/2021 |

Total Attachments: 54

source=AOC Declaration - Patents_111221#page1.tif
source=AOC Declaration - Patents_111221#page2.tif
source=AOC Declaration - Patents_111221#page3.tif
source=AOC Declaration - Patents_111221#page4.tif
source=AOC Declaration - Patents_111221#page5.tif
source=AOC Declaration - Patents_111221#page6.tif
source=AOC Declaration - Patents_111221#page7.tif
source=AOC Declaration - Patents_111221#page8.tif
source=AOC Declaration - Patents_111221#page9.tif
source=AOC Declaration - Patents_111221#page10.tif
source=AOC Declaration - Patents_111221#page11.tif
source=AOC Declaration - Patents_111221#page12.tif
source=AOC Declaration - Patents_111221#page13.tif
source=AOC Declaration - Patents_111221#page14.tif
source=AOC Declaration - Patents_111221#page15.tif
source=AOC Declaration - Patents_111221#page16.tif
source=AOC Declaration - Patents_111221#page17.tif
source=AOC Declaration - Patents_111221#page18.tif
source=AOC Declaration - Patents_111221#page19.tif
source=AOC Declaration - Patents_111221#page20.tif
source=AOC Declaration - Patents_111221#page21.tif
source=AOC Declaration - Patents_111221#page22.tif
source=AOC Declaration - Patents_111221#page23.tif
source=AOC Declaration - Patents_111221#page24.tif
source=AOC Declaration - Patents_111221#page25.tif
source=AOC Declaration - Patents_111221#page26.tif
source=AOC Declaration - Patents_111221#page27.tif
source=AOC Declaration - Patents_111221#page28.tif
source=AOC Declaration - Patents_111221#page29.tif
source=AOC Declaration - Patents_111221#page30.tif
source=AOC Declaration - Patents_111221#page31.tif
source=AOC Declaration - Patents_111221#page32.tif
source=AOC Declaration - Patents_111221#page33.tif
source=AOC Declaration - Patents_111221#page34.tif
source=AOC Declaration - Patents_111221#page35.tif
source=AOC Declaration - Patents_111221#page36.tif
source=AOC Declaration - Patents_111221#page37.tif
source=AOC Declaration - Patents_111221#page38.tif
source=AOC Declaration - Patents_111221#page39.tif
source=AOC Declaration - Patents_111221#page40.tif

source=AOC Declaration - Patents_111221#page41.tif
source=AOC Declaration - Patents_111221#page42.tif
source=AOC Declaration - Patents_111221#page43.tif
source=AOC Declaration - Patents_111221#page44.tif
source=AOC Declaration - Patents_111221#page45.tif
source=AOC Declaration - Patents_111221#page46.tif
source=AOC Declaration - Patents_111221#page47.tif
source=AOC Declaration - Patents_111221#page48.tif
source=AOC Declaration - Patents_111221#page49.tif
source=AOC Declaration - Patents_111221#page50.tif
source=AOC Declaration - Patents_111221#page51.tif
source=AOC Declaration - Patents_111221#page52.tif
source=AOC Declaration - Patents_111221#page53.tif
source=AOC Declaration - Patents_111221#page54.tif

DECLARATION OF REKHA HANU

I, Rekha Hanu, declare:

1. I am a Vice President, Associate General Counsel and Chief IP Counsel for Akorn Operating Company LLC (“AOC”). It is in this capacity in which I make this declaration. I am over the age of 18 and if called as a witness could testify competently and with personal knowledge to the matters set forth herein.

2. AOC as assignor and Medtech Products Inc. (“Medtech”) as assignee executed that certain Assignment of Intellectual Property Rights, dated August 2, 2021, and recorded on August 19, 2021, at Reel/Frame 057222/0489 (“Medtech Assignment”). A true and correct copy of the Medtech Assignment is attached hereto as Exhibit 1.

3. The patent assignment schedule to the Medtech Assignment (Exhibit A to the Medtech Assignment) identified the ten (10) patent properties assigned to Medtech. The properties assigned from AOC to Medtech and properly recorded at Reel/Frame 057222/0489 are as follows:

| <u>Title</u> | <u>App. No.</u> | <u>Reg. No.</u> | <u>Reg. Date</u> | <u>Current Owner</u> |
|--|------------------------|------------------------|-------------------------|-----------------------------|
| Cleanser Compositions and Methods for Using the Same | 16997148 | N/A | N/A | Medtech Products, Inc. |
| Cleanser Compositions and Methods for Using the Same | 17211952 | N/A | N/A | Medtech Products, Inc. |
| Cleanser Composition and Methods for Using the Same | 12771246 | 8231912 | 07-31-12 | Medtech Products, Inc. |
| Cleanser Compositions and Methods for Using the Same | 14722252 | N/A | N/A | Medtech Products, Inc. |
| Cleanser Compositions and Methods for Using the Same | 13539531 | 8449928 | 05-28-13 | Medtech Products, Inc. |
| Cleanser Compositions | 13871133 | 8932653 | 01-13-15 | Medtech Products, |

| <u>Title</u> | <u>App. No.</u> | <u>Reg. No.</u> | <u>Reg. Date</u> | <u>Current Owner</u> |
|---|-----------------|-----------------|------------------|------------------------|
| and Methods for Using the Same | | | | Inc. |
| Cleanser Compositions and Methods for Using the Same | 14528420 | 9050288 | 06-09-15 | Medtech Products, Inc. |
| Method of Treatment Using a Therapeutic Agent for Intranasal Administration | 14082890 | 8900643 | 12-02-14 | Medtech Products, Inc. |
| Method of Treatment Using a Therapeutic Agent for Intranasal Administration | 14464177 | 9301988 | 04-05-16 | Medtech Products, Inc. |
| Methods and Compositions for the Treatment of Infection or Infectious Colonization of the Eyelid, Ocular Surface, Skin or Ear | 13523512 | 8535736 | 09-17-13 | Medtech Products, Inc. |

5. In addition to the above assigned and properly recorded properties, the patent assignment cover sheet to the Medtech Assignment (attached hereto as Exhibit 2) erroneously included the five (5) patent applications and registrations in the chart below that were not listed in the assignment schedule to the Medtech Assignment, and were not assigned to Medtech (these 5 properties are hereinafter referred to as the “AOC Patents”). As shown in the recorded chain of title for the AOC Patents, the last actual assignments of the AOC Patents are recorded at Reel/Frame 055326/0694, which confirms AOC as the current assignee and owner of the AOC Patents.

6. Each of the below applications and registrations belong to AOC and not to Medtech – indeed they were never assigned to Medtech. As such, AOC hereby requests that the USPTO correct the improper recordation made at Reel/Frame 057222/0489 by nullifying the recordation with respect to the AOC Patents, namely, the following U.S. patent applications and

registrations:

| <u>Title</u> | <u>App. No.</u> | <u>Reg. No.</u> | <u>Reg. Date</u> | <u>Current Owner</u> |
|--|-----------------|-----------------|------------------|-----------------------------|
| Aqueous Gel Formulation and Method for Inducing Topical Anesthesia | 13961453 | 8759401 | 06-24-14 | Akorn Operating Company LLC |
| Stable Pentobarbital Formulation | 14617404 | 9517269 | 12-13-16 | Akorn Operating Company LLC |
| Methods of Sterilizing Drugs | 15674791 | 10426834 | 10-01-19 | Akorn Operating Company LLC |
| Ready to Use Ephedrine Formulation and its Uses Thereof | 62955249 | N/A | N/A | Akorn Operating Company LLC |
| Ophthalmic Suspension Compositions and Process for the Preparation of Same | 62991743 | N/A | N/A | Akorn Operating Company LLC |

7. AOC, as the last correct owner and assignee, has been and continues to be the owner of the AOC Patents shown in the listing above.

I declare under penalty of perjury, pursuant to 28 U.S.C. § 1746(2), that the foregoing is true and correct to the best of my knowledge.

Date: November 12, 2021


DocuSigned by:

 61C0D79C10A4130
 Rekha Hanu

EXHIBIT 1

Assignment of Intellectual Property Rights

WHEREAS, Akorn Operating Company LLC, a Delaware limited liability company ("Seller"), and Medtech Products Inc., a Delaware corporation ("Buyer"), are parties to that certain Asset Purchase Agreement dated as of May 27, 2021 (the "Asset Purchase Agreement");

WHEREAS, Seller confirms that certain intellectual property listed in Exhibit A which is registered in the name of Advanced Vision Research, Inc. was assigned to Seller pursuant to that certain Patent Assignment Agreement between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co, LLC, on the one hand, and Seller, on the other hand, dated October 1, 2020 and that certain Trademark Assignment Agreement between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co, LLC, on the one hand, and Seller, on the other hand dated October 1, 2020, both of which are attached as Exhibit B; and

WHEREAS, pursuant to the Asset Purchase Agreement, Seller is assigning and transferring the Transferred Owned Intellectual Property Rights (as such term is defined in the Asset Purchase Agreement) to Buyer;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Seller hereby assigns, grants, transfers and conveys (and agrees to assign, grant, transfer and convey) to Buyer, its successors and assigns all of its right, title and interest throughout the world in and to the Transferred Owned Intellectual Property Rights (including, as applicable, all copyrights, patents, trademarks, trade secrets and other intellectual property rights and all of its other rights in the Transferred Owned Intellectual Property Rights that may now or hereafter be vested) including the intellectual property listed in Exhibit A, together with all national, foreign, state and common law registrations, applications for registration and renewals and extensions thereof; all goodwill associated therewith; and all benefits, privileges, causes of action and remedies relating to any of the foregoing hereafter accrued (including, without limitation, the rights to apply for and maintain all such registrations, renewals and/or extensions; to sue for infringements or other violations of its rights in the Transferred Owned Intellectual Property Rights; and to settle and retain proceeds from any such actions).

Seller also agrees to execute such written instruments, extend such other cooperation and perform such other acts as may be necessary, in the reasonable opinion of Buyer, to register a copyright or trademark, obtain a patent or otherwise enforce Buyer's rights in the Transferred Owned Intellectual Property Rights all of the foregoing at Buyer's sole cost and expense; and Seller hereby irrevocably appoint Buyer and any of its officers as Seller's attorney in fact to undertake such acts in Seller's name.

This assignment agreement, together with the Asset Purchase Agreement and the other Ancillary Agreements (as such term is defined in the Asset Purchase Agreement) constitute the entire agreement between Seller and Buyer concerning the subject matter hereof and supersedes all prior or contemporaneous discussions, communications and agreements, whether oral or written, between Seller and Buyer relating to the subject matter hereof.

[Signature page follows]

IN WITNESS WHEREOF, Buyer and Seller have caused this Assignment Agreement to be duly executed as of August 2, 2021 by their respective officers thereunto duly authorized.

BUYER:

MEDTECH PRODUCTS INC.

By: 

Name: Christine Sacco

Title: Chief Financial Officer


[Signature Page to Assignment of Intellectual Property Rights]

PATENT
REEL: 058104 FRAME: 0749

SELLER:

AKORN OPERATING COMPANY LLC

By:


Name: Douglas S. Boothe

Title: President and CEO

[Signature Page to Assignment of Intellectual Property Rights]

PATENT
REEL: 058104 FRAME: 0750

Exhibit A

Trademarks

| # | Title | Jurisdiction | App. No. | App. Date | Reg. No. | Reg. Date | Owner |
|-----|---|--------------|------------|------------|-----------|------------|-----------------------------|
| 1. | DESIGN ONLY | USA | 88/581,415 | 8/16/2019 | N/A | N/A | Akorn Operating Company LLC |
| 2. | RESTORES EYES NATURAL BALANCE CLEANSES EYELIDS AND LASHES NOURISHES EYES TO PROMOTE HEALTHY TEARS and Design | USA | 88/070,824 | 8/9/2018 | N/A | N/A | Akorn Operating Company LLC |
| 3. | STERILID | New Zealand | 1131346 | 10/1/2019 | N/A | N/A | Akorn Operating Company LLC |
| 4. | THERAREARS EXTRA | USA | 88/047,652 | 7/23/2018 | N/A | N/A | Akorn Operating Company LLC |
| 5. | RESTORES + CLEANSES +NOURISHES and Design | USA | 88/072,677 | 8/9/2018 | N/A | N/A | Akorn Operating Company LLC |
| 6. | HYDROLOCK | USA | 90/552,357 | 3/1/2021 | N/A | N/A | Akorn Operating Company LLC |
| 7. | DESIGN ONLY | USA | 88/581,415 | 8/16/2019 | N/A | N/A | Akorn Operating Company LLC |
| 8. | DIABETIC TUSSIN | USA | 74389373 | 5/4/1993 | 1,861,344 | 11/1/1994 | Akorn Operating Company LLC |
| 9. | FAST AND FIERCE RELIEF | USA | 87007235 | 4/20/2016 | 5,355,854 | 12/12/2017 | Akorn Operating Company LLC |
| 10. | HEADACHE BUSTER | Canada | 1449250 | 8/24/2009 | TMA787365 | 1/14/2011 | Akorn Operating Company LLC |
| 11. | JEFFREY P. GILBARD, MD | USA | 85121025 | 9/1/2010 | 4,556,180 | 6/24/2014 | Akorn Operating Company LLC |
| 12. | MAGINEX | Canada | 1083318 | 11/20/2000 | TMA641833 | 6/13/2005 | Akorn Operating Company LLC |

| # | Title | Jurisdiction | App. No. | App. Date | Reg. No. | Reg. Date | Owner |
|-----|--------------------------------------|--------------|-------------------|------------|-------------------|------------|-----------------------------|
| 13. | MAGINEX | USA | 76052135 | 5/19/2000 | 2,541,622 | 2/19/2002 | Akorn Operating Company LLC |
| 14. | MAG-OX 400 | USA | 75576028 | 10/23/1998 | 2,633,768 | 10/15/2002 | Akorn Operating Company LLC |
| 15. | MASTER OF MAGNESIUM | USA | 87007233 | 4/20/2016 | 5,355,853 | 12/12/2017 | Akorn Operating Company LLC |
| 16. | MULTI-BETIC | USA | 86210334 | 3/4/2014 | 4,613,666 | 9/30/1994 | Akorn Operating Company LLC |
| 17. | OSMO-CORRECTION | USA | 85967253 | 6/22/2013 | 4,837,201 | 10/20/2015 | Akorn Operating Company LLC |
| 18. | PHARMACEUTICAL GRADE (& design) | USA | 78329276 | 11/18/2003 | 3,272,765 | 7/31/2007 | Akorn Operating Company LLC |
| 19. | RESTORES EYES NATURAL BALANCE | USA | 85967251 | 6/22/2013 | 4,846,473 | 11/3/2015 | Akorn Operating Company LLC |
| 20. | SINUS BUSTER | Canada | 1378181 | 1/7/2008 | TMA733034 | 1/22/2009 | Akorn Operating Company LLC |
| 21. | SINUS BUSTER | USA | 78862364 | 4/16/2006 | 3,194,160 | 1/2/2007 | Akorn Operating Company LLC |
| 22. | SINUS BUSTER ALL NATURAL NASAL SPRAY | USA | 78850704 | 3/30/2006 | 3,503,088 | 9/16/2008 | Akorn Operating Company LLC |
| 23. | SINUS GENIE | Canada | 1378171 | 1/7/2008 | TMA732672 | 1/19/2009 | Akorn Operating Company LLC |
| 24. | STERILID | Australia | 1064550 | 7/12/2005 | 1064550 | 7/12/2005 | Akorn Operating Company LLC |
| 25. | STERILID | EU | 4549721 | 7/14/2005 | 4549721 | 6/14/2006 | Akorn Operating Company LLC |
| 26. | STERILID | India | 1376561 | 8/8/2005 | 1376561 | 8/8/2005 | Akorn Operating Company LLC |
| 27. | STERILID | Mexico | 731418 | 7/29/2005 | 907,931 | 11/16/2005 | Akorn Operating Company LLC |
| 28. | STERILID | New Zealand | 1131346 | 10/1/2019 | 1131346 | 2/2/2021 | Akorn Operating Company LLC |
| 29. | STERILID | UK | UK009045497 21 | 7/14/2005 | UK009045497 21 | 6/14/2006 | Akorn Operating Company LLC |

| # | Title | Jurisdiction | App. No. | App. Date | Reg. No. | Reg. Date | Owner |
|-----|-----------------------|------------------------|------------|------------|-----------|------------|-----------------------------|
| 30. | STERILID | USA | 78459733 | 7/30/2004 | 3,140,041 | 9/5/2006 | Akorn Operating Company LLC |
| 31. | THERA LID | Canada | 1387723 | 3/17/2008 | TMA766079 | 5/7/2010 | Akorn Operating Company LLC |
| 32. | THERA TEARS | EU | 2996155 | 1/3/2003 | 2996155 | 10/14/2004 | Akorn Operating Company LLC |
| 33. | THERA TEARS | Mexico | 731417 | 7/29/2005 | 902036 | 9/28/2005 | Akorn Operating Company LLC |
| 34. | THERA TEARS | USA | 88457133 | 6/3/2019 | 5,943,133 | 12/24/2019 | Akorn Operating Company LLC |
| 35. | THERA TEARS STERLILID | USA | 78459728 | 7/30/2004 | 3,181,614 | 12/5/2006 | Akorn Operating Company LLC |
| 36. | THERA TEARS | USA | 74615598 | 12/27/1994 | 2,041,112 | 10/27/1997 | Akorn Operating Company LLC |
| 37. | THERAPY FOR YOUR EYES | USA | 86260607 | 4/23/2014 | 4,843,058 | 10/27/2015 | Akorn Operating Company LLC |
| 38. | THERATEARS EXTRA | USA | 87049747 | 5/25/2016 | 5,586,699 | 10/16/2018 | Akorn Operating Company LLC |
| 39. | THERATEARS | Australia | 7301 82 | 3/18/1997 | 7301 82 | 3/18/1997 | Akorn Operating Company LLC |
| 40. | THERATEARS | Canada | 1085366 | 12/4/2000 | TMA573256 | 1/8/2003 | Akorn Operating Company LLC |
| 41. | THERATEARS | Canada | 1153395 | 9/23/2002 | TMA641310 | 6/3/2005 | Akorn Operating Company LLC |
| 42. | THERATEARS | EU | 2153476 | 3/22/2001 | 2153476 | 7/16/2002 | Akorn Operating Company LLC |
| 43. | THERATEARS | Guatemala | 2014000962 | 2/4/2014 | 201476 | 11/13/2014 | Akorn Operating Company LLC |
| 44. | THERATEARS | India | 1376560 | 8/8/2005 | 1376560 | 8/8/2005 | Akorn Operating Company LLC |
| 45. | THERATEARS | International Register | 1197342 | 1/21/2014 | 1197342 | 1/21/2014 | Akorn Operating Company LLC |
| 46. | THERATEARS | Lebanon | N/A | N/A | 155229 | 2/5/2014 | Akorn Operating Company LLC |

| # | Title | Jurisdiction | App. No. | App. Date | Reg. No. | Reg. Date | Owner |
|-----|---------------------------|------------------|-------------------|-----------|-------------------|------------|-----------------------------|
| 47. | THERATEARS | New Zealand | 274324 | 3/19/1997 | 274324 | 10/17/1997 | Akorn Operating Company LLC |
| 48. | THERATEARS | Norway (IR) | 1197342 | 1/21/2014 | 1197342 | 1/21/2014 | Akorn Operating Company LLC |
| 49. | THERATEARS | South Africa | 2014/01774 | 1/24/2014 | 2014/01774 | 7/30/2015 | Akorn Operating Company LLC |
| 50. | THERATEARS | UK | UK009021534 76 | 3/22/2001 | UK009021534 76 | EXPIRED | Akorn Operating Company LLC |
| 51. | THERATEARS | Singapore (IR) | 1197342 | 1/21/2014 | 1197342 | 1/21/2014 | Akorn Operating Company LLC |
| 52. | THERATEARS | Switzerland (IR) | 1197342 | 1/21/2014 | 1197342 | 1/21/2014 | Akorn Operating Company LLC |
| 53. | THERATEARS | USA | 76427523 | 7/5/2002 | 2,770,1 88 | 9/30/2003 | Akorn Operating Company LLC |
| 54. | THERATEARS STERILID | USA | 78459728 | 7/30/2004 | 3,181,614 | 12/5/2006 | Akorn Operating Company LLC |
| 55. | TYPE YOU | Canada | 1728450 | 5/15/2015 | TMA1040395 | 7/11/2019 | Akorn Operating Company LLC |
| 56. | TYPE YOU | USA | 86631044 | 5/15/2015 | 5,291,486 | 9/19/2017 | Akorn Operating Company LLC |
| 57. | TYPE YOU DIABETIC CARE | Canada | 1776093 | 4/7/2016 | TMA1047727 | 8/8/2019 | Akorn Operating Company LLC |
| 58. | TYPE YOU DIABETIC CARE | USA | 86966811 | 4/6/2016 | 5,297,364 | 9/26/2017 | Akorn Operating Company LLC |
| 59. | ZOSTRIX | USA | 78660833 | 6/29/2005 | 3,106,587 | 6/20/2006 | Akorn Operating Company LLC |
| 60. | ZOSTRIX | USA | 73576274 | 1/6/1986 | 1,423,561 | 1/6/1987 | Akorn Operating Company LLC |
| 61. | THERATEARS | Kuwait | N/A | N/A | 130439 | 2/17/2014 | Akorn Operating Company LLC |
| 62. | URO-MAG | USA | 72450878 | 3/8/1973 | 974841 | 12/18/1973 | Akorn Operating Company LLC |

Patents

| # | Title | Jurisdiction | App. No. | App. Date | Reg. No. | Reg. Date | Owner |
|-----|--|--------------|------------|-----------|------------|-----------|-----------------------------|
| 1. | Cleanser compositions and methods for using the same | U.S. | 16/997,148 | 8/19/2020 | N/A | N/A | Akorn Operating Company LLC |
| 2. | Cleanser compositions and methods for using the same | U.S. | 17/211,952 | 3/25/2021 | N/A | N/A | Akorn Operating Company LLC |
| 3. | Cleanser composition and methods for using the same | U.S. | 12/771,246 | 4/30/2010 | 8231912 | 7/31/2012 | Akorn Operating Company LLC |
| 4. | Cleanser composition and methods for using the same | U.S. | 14/722,252 | 5/27/2015 | ABANDONED | ABANDONED | Akorn Operating Company LLC |
| 5. | Cleanser Compositions And Methods For Using The Same | Australia | 2010242866 | 4/30/2010 | 2010242866 | 4/30/2010 | Akorn Operating Company LLC |
| 6. | Cleanser Compositions And Methods For Using The Same | Austria | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 7. | Cleanser Compositions And Methods For Using The Same | Bulgaria | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 8. | Cleanser Compositions And Methods For Using The Same | Canada | CA2760591 | 4/30/2010 | CA2760591 | 1/2/2018 | Akorn Operating Company LLC |
| 9. | Cleanser Compositions And Methods For Using The Same | Cyprus | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 10. | Cleanser Compositions And Methods For Using The Same | Denmark | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 11. | Cleanser Compositions And Methods For Using The Same | Estonia | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 12. | Cleanser Compositions And Methods For Using The Same | European | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 13. | Cleanser Compositions And Methods For Using The Same | Finland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating |

| | | | | | | | |
|-----|--|-------------|------------|-----------|---------|-----------|--------------------------------------|
| | | | | | | | Company LLC |
| 14. | Cleanser Compositions And Methods For Using The Same | France | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 15. | Cleanser Compositions And Methods For Using The Same | Germany | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 16. | Cleanser Compositions And Methods For Using The Same | Greece | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 17. | Cleanser Compositions And Methods For Using The Same | Iceland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 18. | Cleanser Compositions And Methods For Using The Same | Ireland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 19. | Cleanser Compositions And Methods For Using The Same | Italy | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 20. | Cleanser Compositions And Methods For Using The Same | Latvia | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 21. | Cleanser Compositions And Methods For Using The Same | Lithuania | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 22. | Cleanser Compositions And Methods For Using The Same | Netherlands | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 23. | Cleanser Compositions And Methods For Using The Same | New Zealand | 596254 | 11/7/2011 | 596254 | 10/1/2013 | Akorn Operating Company LLC |
| 24. | Cleanser Compositions And Methods For Using The Same | Norway | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 25. | Cleanser Compositions And Methods For Using The Same | Poland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 26. | Cleanser Compositions And Methods For Using The Same | Portugal | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |

| | | | | | | | |
|-----|---|----------------|------------|------------|------------|-----------|-----------------------------|
| 27. | Cleanser Compositions And Methods For Using The Same | Romania | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 28. | Cleanser Compositions And Methods For Using The Same | Spain | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 29. | Cleanser Compositions And Methods For Using The Same | Sweden | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 30. | Cleanser Compositions And Methods For Using The Same | Switzerland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 31. | Cleanser compositions and methods for using the same | U.S. | 13/539,531 | 7/2/2012 | 8449928 | 5/28/2013 | Akorn Operating Company LLC |
| 32. | Cleanser compositions and methods for using the same | U.S. | 13/871,133 | 4/26/2013 | 8932653 | 1/13/2015 | Akorn Operating Company LLC |
| 33. | Cleanser compositions and methods for using the same | U.S. | 14/528,420 | 10/30/2014 | 9050288 | 6/9/2015 | Akorn Operating Company LLC |
| 34. | Cleanser Compositions And Methods For Using The Same | United Kingdom | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| 35. | Method of treatment using a therapeutic agent for intranasal administration | U.S. | 14/082,890 | 11/18/2013 | 8900643 | 12/2/2014 | Akorn Operating Company LLC |
| 36. | Method of treatment using a therapeutic agent for intranasal administration | U.S. | 14/464,177 | 8/20/2014 | 9301988 | 4/5/2016 | Akorn Operating Company LLC |
| 37. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Australia | 2007238666 | 4/12/2007 | 2007238666 | 8/22/2013 | Akorn Operating Company LLC |
| 38. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Austria | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| | | | | | | | |
|-----|---|----------|---------|-----------|---------|-----------|-----------------------------|
| 39. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Canada | 2650136 | 4/12/2007 | 2650136 | 7/7/2015 | Akorn Operating Company LLC |
| 40. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Denmark | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 41. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Estonia | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 42. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | European | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 43. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Finland | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 44. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | France | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 45. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Germany | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 46. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The | Greece | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| | | | | | | | |
|-----|---|----------------|------------|-----------|---------|-----------|-----------------------------|
| | Eyelid, Ocular Surface, Skin Or Ear | | | | | | |
| 47. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Italy | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 48. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Liechtenstein | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 49. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | New Zealand | 571810 | 10/7/2008 | 571810 | 10/8/2012 | Akorn Operating Company LLC |
| 50. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Spain | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 51. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Sweden | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 52. | Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Switzerland | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| 53. | Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear | U.S. | 13/523,512 | 6/14/2012 | 8535736 | 9/17/2013 | Akorn Operating Company LLC |
| 54. | Methods And Compositions For The Treatment Of Infection Or Infectious | United Kingdom | 7755402 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| | | | | | | | |
|--|---|--|--|--|--|--|--|
| | Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | | | | | | |
|--|---|--|--|--|--|--|--|

Exhibit B

[See attached]

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6373911

| | |
|------------------------------|----------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|-------------------------------|----------------|
| AKORN, INC. | 10/01/2020 |
| ADVANCED VISION RESEARCH, LLC | 10/01/2020 |
| HI-TECH PHARMACAL CO., LLC | 10/01/2020 |

RECEIVING PARTY DATA

| | |
|------------------------|------------------------------|
| Name: | AKORN OPERATING COMPANY, LLC |
| Street Address: | 1925 W. FIELD COURT |
| City: | LAKE FOREST |
| State/Country: | ILLINOIS |
| Postal Code: | 60045 |

PROPERTY NUMBERS Total: 13

| Property Type | Number |
|---------------------|----------|
| Application Number: | 14722252 |
| Application Number: | 62955249 |
| Application Number: | 62991743 |
| Application Number: | 13961453 |
| Application Number: | 12771246 |
| Application Number: | 13539531 |
| Application Number: | 13871133 |
| Application Number: | 14528420 |
| Application Number: | 14082890 |
| Application Number: | 14464177 |
| Application Number: | 13523512 |
| Application Number: | 15674791 |
| Application Number: | 14617404 |

CORRESPONDENCE DATA

Fax Number: (312)862-2200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128622000

Email: rob.soneson@kirkland.com
Correspondent Name: ROB SONESON
Address Line 1: 300 N LASALLE
Address Line 2: KIRKLAND & ELLIS LLP
Address Line 4: CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 14581-66-RFS

NAME OF SUBMITTER: ROB SONESON

SIGNATURE: /rsoneson/

DATE SIGNED: 10/28/2020

Total Attachments: 14

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page1.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page2.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page3.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page4.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page5.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page6.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page7.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page8.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page9.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page10.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page11.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page12.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page13.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_ (72078373_1)#page14.tif

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”) and is by and between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co., LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the patents and patent applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Patents**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which APA Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Assigned Patents which are part of the Acquired Assets; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(b) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. **Assignment.** Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s right, title, and interest throughout the world in and to the Assigned Patents, including any continuation, continuation-in-part, divisional, extension, substitution, re-examination, or reissue thereof or any legal equivalent in the United States or a foreign country for the full term or terms for which the same may be granted, including the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties,

damages, and payments hereafter due or payable with respect to the Assigned Patents (except to the extent arising under prior patent license agreements included in the Excluded Contracts), the right to prosecute, maintain and defend the Assigned Patents before any public or private agency, office or registrar, and all claims, causes of action and rights to sue for past, present and future infringement or unconsented use of the Assigned Patents. Each Assignor authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Patents and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Patents in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Patents with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Patents with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement (including the Schedules and exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of the Purchase Agreement and this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.


7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:

AKORN, INC.

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel, and Secretary


ADVANCED VISION RESEARCH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

HI-TECH PHARMACAL CO., LLC


By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel, and Secretary

EXHIBIT A

Patent Applications

| Title | Jurisdiction | Application No. | Filing Date | Status | Current Owner of Record |
|--|--------------|-----------------|-------------|---------|-----------------------------|
| Cleanser compositions and methods for using the same | U.S. | 14/722,252 | 5/27/2015 | Pending | Akorn Operating Company LLC |
| Ready to use ephedrine formulation and its uses thereof | U.S. | 62/955,249 | 12/30/2019 | Pending | Akorn Operating Company LLC |
| Ophthalmic Suspension Compositions and Process for the Preparation of Same | U.S. | 62/991,743 | 3/19/2020 | Pending | Akorn Operating Company LLC |

Patents

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|--|--------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Aqueous gel formulation and method for inducing topical anesthesia | U.S. | 13/961,453 | 8/7/2013 | 8759401 | 6/24/2014 | Akorn Operating Company LLC |
| Cleanser composition and methods for using the same | U.S. | 12/771,246 | 4/30/2010 | 8231912 | 7/31/2012 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|--|--------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Cleanser Compositions And Methods For Using The Same | Australia | 2010242866 | 4/30/2010 | 2010242866 | 4/30/2010 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Austria | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Bulgaria | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Cyprus | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Denmark | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Estonia | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | European | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|--|--------------|---------------------------------|-------------|------------|-------------------|-----------------------------|
| Cleanser Compositions And Methods For Using The Same | Finland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | France | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Germany | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Greece | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Iceland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Ireland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Italy | 502018000011485 (10770410.8) | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|--|--------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Cleanser Compositions And Methods For Using The Same | Latvia | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Lithuania | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Netherlands | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | New Zealand | 596254 | 11/7/2011 | 596254 | 10/1/2013 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Norway | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Poland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Portugal | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|--|--------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Cleanser Compositions And Methods For Using The Same | Romania | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Spain | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Sweden | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser Compositions And Methods For Using The Same | Switzerland | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Cleanser compositions and methods for using the same | U.S. | 13/539,531 | 7/2/2012 | 8449928 | 5/28/2013 | Akorn Operating Company LLC |
| Cleanser compositions and methods for using the same | U.S. | 13/871,133 | 4/26/2013 | 8932653 | 1/13/2015 | Akorn Operating Company LLC |
| Cleanser compositions and methods for using the same | U.S. | 14/528,420 | 10/30/2014 | 9050288 | 6/9/2015 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|---|----------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Cleanser Compositions And Methods For Using The Same | United Kingdom | 10770410.8 | 4/30/2010 | 2424374 | 1/17/2018 | Akorn Operating Company LLC |
| Method of treatment using a therapeutic agent for intranasal administration | U.S. | 14/082,890 | 11/18/2013 | 8900643 | 12/2/2014 | Akorn Operating Company LLC |
| Method of treatment using a therapeutic agent for intranasal administration | U.S. | 14/464,177 | 8/20/2014 | 9301988 | 4/5/2016 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Australia | 2007238666 | 4/12/2007 | 2007238666 | 08/22/2013 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Austria | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Canada | 2650136 | 4/12/2007 | 2650136 | 7/7/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Denmark | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|---|--------------|---------------------------------|-------------|------------|-------------------|-----------------------------|
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Estonia | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | European | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Finland | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | France | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Germany | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Greece | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Italy | 502015000064091 (07755402.0) | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|---|----------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Liechtenstein | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | New Zealand | 571810 | 10/7/2008 | 571810 | 10/8/2012 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Spain | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Sweden | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | Switzerland | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |
| Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear | U.S. | 13/523,512 | 6/14/2012 | 8535736 | 9/17/2013 | Akorn Operating Company LLC |
| Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear | United Kingdom | 07755402.0 | 4/12/2007 | 2018103 | 8/26/2015 | Akorn Operating Company LLC |

| Title | Jurisdiction | Application No. | Filing Date | Patent No. | Registration Date | Current Owner of Record |
|----------------------------------|--------------|-----------------|-------------|------------|-------------------|-----------------------------|
| Methods of sterilizing drugs | U.S. | 15/674,791 | 8/11/2017 | 10426834 | 10/1/2019 | Akorn Operating Company LLC |
| Stable pentobarbital formulation | U.S. | 14/617,404 | 2/9/2015 | 9517269 | 12/13/2016 | Akorn Operating Company LLC |

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM610993

| | | | |
|---|--|---|-------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Advanced Vision Research, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Hi-Tech Pharmacal Co., LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Akorn Animal Health, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | Akorn Operating Company LLC | | |
| Street Address: | 1925 W. Field Court | | |
| City: | Lake Forest | | |
| State/Country: | ILLINOIS | | |
| Postal Code: | 60045 | | |
| Entity Type: | Limited Liability Company: DELAWARE | | |
| PROPERTY NUMBERS Total: 8 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 88581415 | | |
| Serial Number: | 88677127 | DETOMISED | |
| Serial Number: | 88164134 | MACUTRITION | |
| Serial Number: | 88677131 | PROPOSED | |
| Serial Number: | 88072677 | RESTORES + CLEANSSES + NOURISHES | |
| Serial Number: | 88070824 | RESTORES EYES NATURAL BALANCE CLEANSSES E | |
| Serial Number: | 87413349 | STERI-OPTICS | |
| Serial Number: | 88047652 | THERATEARS EXTRA | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 3128622200 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Phone: | 3128622000 | | |
| Email: | rob.soneson@kirkland.com | | |
| Correspondent Name: | ROB SONESON | | |
| Address Line 1: | 300 N LASALLE | | |

CH \$215.00 88581415

Address Line 2: KIRKLAND & ELLIS LLP
Address Line 4: CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 14581-66-RFS

NAME OF SUBMITTER: Rob Soneson

SIGNATURE: /rsoneson/

DATE SIGNED: 11/25/2020

Total Attachments: 14

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page1.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page2.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page3.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page4.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page5.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page6.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page7.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page8.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page9.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page10.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page11.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page12.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page13.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page14.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”), and is by and between Akorn, Inc., Advanced Vision Research, LLC, Hi-Tech Pharmacal Co., LLC, Akorn Animal Health, LLC, Clover Pharmaceuticals LLC, Akorn International S.À.R.L., Oak Pharmaceuticals, LLC., Inspire Pharmaceuticals, LLC, and VersaPharm LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the trademark registrations and applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Trademarks**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Acquired Assets, which assets include the Assigned Trademarks; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(c) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. Assignment. Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s worldwide right, title, and interest throughout the world in and to the Assigned Trademarks, together with that portion of such Assignor’s business connected with the use of and

symbolized by the Assigned Trademarks, and all past and present goodwill associated therewith or symbolized thereby, all common law rights thereto, all registrations that have been or may be granted thereon, all applications for registrations thereof, the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties, damages, and payments hereafter due or payable with respect to the Assigned Trademarks, the right to register, prosecute, maintain, and defend the Assigned Trademarks before any public or private agency, office, or registrar, and all claims, causes of action, and rights to sue for past, present, and future infringement or unconsented use of the Assigned Trademarks. Each of the Assignors authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Trademarks and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Trademarks in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Trademarks with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Trademarks with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement, (including the Schedules and

exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct, or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties hereto agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.

7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:


AKORN, INC.

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary


ADVANCED VISION RESEARCH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

HI-TECH PHARMACAL CO., LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN ANIMAL HEALTH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

CLOVER PHARMACEUTICALS LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN INTERNATIONAL S.À.R.L.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

OAK PHARMACEUTICALS, LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

INSPIRE PHARMACEUTICALS, LLC.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

VERSAPHARM LLC


By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary

[SIGNATURE PAGE TO TRADEMARK ASSIGNMENT AGREEMENT]

PATENT
REEL: 058104 FRAME: 0785

EXHIBIT A

Trademark Applications

| TradeMark | Title | Country | Application No. | Filing Date | Status | Assignor |
|------------------|--------------|--------------------------|------------------------|--------------------|---------------|-------------------------------|
| AKORN | | Albania (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | | South Korea (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | | Bangladesh | 202646 | 10/2/2016 | Pending | Akorn, Inc. |
| AKORN | | Botswana | BW/M/2016/00839 | 9/27/2016 | Pending | Akorn, Inc. |
| AKORN | | China (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | | Ethiopia | FTM/8414/17 | 3/1/2017 | Pending | Akorn, Inc. |
| AKORN | | Indonesia | D002016047722 | 10/6/2016 | Pending | Akorn, Inc. |
| AKORN | | Kuwait | 183751 | 9/25/2016 | Pending | Akorn, Inc. |
| AKORN | | Nigeria | F/TM/O/2016/109648 | 10/4/2016 | Pending | Akorn, Inc. |
| AKORN | | Qatar | 110397 | 11/29/2016 | Pending | Akorn, Inc. |
| AKORN | | South Africa | 2016/26761 | 9/19/2016 | Pending | Akorn, Inc. |
| AKORN | | Sri Lanka | 211594 | 9/27/2016 | Pending | Akorn, Inc. |
| AKORN | | Yemen | 77345 | 12/17/2016 | Pending | Akorn, Inc. |
| STERILID | | New Zealand | 1131346 | 10/1/2019 | Pending | Advanced Vision Research, LLC |
| THERATEARS | | Norway (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | | Singapore (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | | South Africa | 2014/01774 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | | Switzerland (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| AKORN | | India | 3537421 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | | Nigeria | F/TM/O/2014/18707 | 6/18/2014 | Pending | Akorn Inc. |
| AK-BETAX | | Nigeria | F/TM/O/2014/18595 | 6/16/2014 | Pending | Akorn Inc. |
| AK-BRIMON | | Nigeria | F/TM/O/2014/18626 | 6/17/2014 | Pending | Akorn Inc. |
| AK-CMC | | Nigeria | F/TM/O/2014/18706 | 6/18/2014 | Pending | Akorn Inc. |
| AK-CROMO | | Nigeria | F/TM/O/2014/18630 | 6/17/2014 | Pending | Akorn Inc. |
| AK-DRAZINE | | Nigeria | F/TM/O/2014/18625 | 6/17/2014 | Pending | Akorn Inc. |
| AK-KETOR | | Nigeria | F/TM/O/2014/18622 | 6/17/2014 | Pending | Akorn Inc. |
| AK-LATAN | | Nigeria | F/TM/O/2014/18623 | 6/17/2014 | Pending | Akorn Inc. |

| Title | Country | Application No. | Filing Date | Status | Assignor |
|---|---------|-------------------|-------------|---------|---------------------------------|
| AK-MELLO | Nigeria | F/TM/O/2014/18705 | 6/18/2014 | Pending | Akom Inc. |
| AK-NAPHALIN | Nigeria | F/TM/O/2014/18704 | 6/18/2014 | Pending | Akom Inc. |
| AK-NEO-P | Nigeria | F/TM/O/2014/18592 | 6/16/2014 | Pending | Akom Inc. |
| AK-TEARS | Nigeria | F/TM/O/2014/18593 | 6/16/2014 | Pending | Akom Inc. |
| AK-TIFEN | Nigeria | F/TM/O/2014/18578 | 6/16/2014 | Pending | Akom Inc. |
| AKGENTA | Nigeria | F/TM/O/2014/18703 | 6/18/2014 | Pending | Akom Inc. |
| AKORNAPH | Nigeria | F/TM/O/2015/70291 | 11/23/2015 | Pending | Akom Inc. |
| AKORNBET | Nigeria | F/TM/O/2015/70285 | 11/23/2015 | Pending | Akom Inc. |
| AKORNCROM | Nigeria | F/TM/O/2015/70288 | 11/23/2015 | Pending | Akom Inc. |
| AKORNTEARS | Nigeria | F/TM/O/2015/70292 | 11/23/2015 | Pending | Akom Inc. |
| AKORNTENAC | Nigeria | F/TM/O/2015/70293 | 11/23/2015 | Pending | Akom Inc. |
| AKORNTIMOL | Nigeria | F/TM/O/2015/70286 | 11/23/2015 | Pending | Akom Inc. |
| AKORNTIFEN | Nigeria | F/TM/O/2015/70287 | 11/23/2015 | Pending | Akom Inc. |
| AKORNTRIX | Nigeria | F/TM/O/2015/70290 | 11/23/2015 | Pending | Akom Inc. |
| AKORN ROLAC | Nigeria | F/TM/O/2015/70294 | 11/23/2015 | Pending | Akom Inc. |
| DESIGN ONLY | USA | 88/581,415 | 8/16/2019 | Pending | Advanced Vision Research, LLC |
| DETOMISED | USA | 88/677,127 | 11/1/2019 | Pending | Akom Animal Health, LLC |
| MACUTRITION | USA | 88/164,134 | 10/22/2018 | Pending | Advanced Vision Research, LLC |
| PROPOSED | USA | 88/677,131 | 11/1/2019 | Pending | Akom Animal Health, LLC |
| RESTORES + CLEANSSES + NOURISHES and Design | USA | 88/072,677 | 8/9/2018 | Pending | Advanced Vision Research, LLC |
| RESTORES EYES NATURAL BALANCE CLEANSSES EYELIDS AND LASHES NOURISHES EYES TO PROMOTE HEALTHY TEARS and Design | USA | 88/070,824 | 8/9/2018 | Pending | Advanced Vision Research, LLC |
| STERI-OPTICS | USA | 87/413,349 | 4/17/2017 | Pending | Hi-Tech Pharmaceutical Co., LLC |
| THERATEARS EXTRA | USA | 88/047,652 | 7/23/2018 | Pending | Advanced Vision Research, LLC |

Registered Trademarks

| Title | Country | Application No. | Registration No. | Assigner |
|--------------------------|------------------|------------------------|-------------------------|-----------------|
| ADVANCING THE NEW VISION | USA | 85114820 | 3954229 | Akorn, Inc. |
| AK-FLUOR | USA | 73652686 | 1464246 | Akorn, Inc. |
| AKORN | Algeria | 164287 | 99676 | Akorn, Inc. |
| AKORN | Australia (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Bosnia (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Canada | 1792618 | TMA987817 | Akorn, Inc. |
| AKORN | Costa Rica | 2016-0009676 | 261950 | Akorn, Inc. |
| AKORN | EUTM (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Guatemala | 2016009653 | 229620 | Akorn, Inc. |
| AKORN | Hong Kong | 303911643 | 303911643 | Akorn, Inc. |
| AKORN | India (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Iceland (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Israel (IR) | 292976 | 292976 | Akorn, Inc. |
| AKORN | Jordan | 149710 | 149710 | Akorn, Inc. |
| AKORN | Kenya | 94117 | 94117 | Akorn, Inc. |
| AKORN | Kosovo | KS/M/2016/1311 | 21362 | Akorn, Inc. |
| AKORN | Lebanon | N/A | 176515 | Akorn, Inc. |
| AKORN | Macedonia (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Malaysia | 2016067189 | 2016067189 | Akorn, Inc. |
| AKORN | Montenegro (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Nepal | 065274 | 2016/65274 | Akorn, Inc. |
| AKORN | New Zealand (IR) | 1063094 | 1336041 | Akorn, Inc. |
| AKORN | Norway (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Panama | 253351-01 | 253351-01 | Akorn, Inc. |
| AKORN | Russia (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Saudi Arabia | 1437028411 | 1437028411 | Akorn, Inc. |
| AKORN | Serbia (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Singapore (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Switzerland (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Taiwan | 105056232 | 01856945 | Akorn, Inc. |
| AKORN | Thailand | 160108644 | 191104966 | Akorn, Inc. |
| AKORN | Turkey (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | UAE | 261898 | 261898 | Akorn, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|----------------------------|------------------------|-----------------|-------------------------------|---------------------------------|
| AKORN | Ukraine (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | United Kingdom (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Uruguay | 441,150 | 441,150 | Akorn, Inc. |
| AKORN | USA | 77589830 | 3,774,019 | Akorn, Inc. |
| AKORN | USA | 86937435 | 5,076,962 | Akorn, Inc. |
| AKTEN | Israel | 291476 | 291476 | Akorn, Inc. |
| AKTEN | USA | 77012922 | 3,631,872 | Akorn, Inc. |
| AKWA TEARS | USA | 75829828 | 2,429,583 | Akorn, Inc. |
| ALLERGY BUSTER | Canada | 1449252 | TMA787366 | Hi-Tech Pharmaceutical Co., LLC |
| ALLERGY BUSTER & DESIGN | EU | 008506347 | 008506347 | Hi-Tech Pharmaceutical Co., LLC |
| AMICAR | USA | 72124870 | 729,648 | Clover Pharmaceuticals LLC |
| ANASED | Canada | 0878555 | TMA526130 | Akorn Animal Health, LLC |
| ANASED | USA | 73815445 | 1,589,685 | Akorn Animal Health, LLC |
| BETIMOL | International Register | 728498 A | 728498 A | Akorn International S.A.R.L. |
| BETIMOL | USA | 74628335 | 1,961,729 | Akorn International S.A.R.L |
| BETIMOL | USA | 79128616 | 4,442,019 (IR No. 728489A) | Akorn International S.A.R.L |
| BUTORPHIC | USA | 77492827 | 3,648,627 | Akorn Animal Health, LLC |
| CAPASTAT | Canada | 0294218 | TMA147966 | Akorn, Inc. |
| CAPASTAT | USA | 72221381 | 808,363 | Akorn, Inc. |
| CHOICE DM | Canada | 0821371 | TMA535139 | Hi-Tech Pharmaceutical Co., LLC |
| CONTROL THE UNCONTROLLABLE | USA | 85961915 | 4,732,151 | Oak Pharmaceuticals, LLC |
| DIABETIC TUSSIN | USA | 74389373 | 1,861,344 | Hi-Tech Pharmaceutical Co., LLC |
| DIADERM | USA | 86025876 | 4,573,615 | Hi-Tech Pharmaceutical Co., LLC |
| EYE RX DIRECT (design) | USA | 86773391 | 5,296,978 | Akorn, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|--|--------------------|-----------------|------------------|---------------------------------|
| FAST AND FIERCE RELIEF | USA | 87007235 | 5,355,854 | Hi-Tech Pharmaceutical Co., LLC |
| AKORN PHARMACAL, INC. | US State/Louisiana | N/A | 658495 | Hi-Tech Pharmaceutical Co., LLC |
| FLURESS | USA | 72203731 | 789,323 | Akorn, Inc. |
| GENT-AK | USA | 73652684 | 1,464,244 | Akorn, Inc. |
| GROUNDLED IN SCIENCE. PROVEN IN PRACTICE | USA | 85961910 | 4,748,523 | Oak Pharmaceuticals, LLC |
| HEADACHE BUSTER | Canada | 1449250 | TMA787365 | Hi-Tech Pharmaceutical Co., LLC |
| IC-GREEN | Canada | 0855183 | TMA531645 | Akorn, Inc. |
| IC-GREEN | Denmark | VA 003089 1997 | VR 199703234 | Akorn, Inc. |
| IC-GREEN | France | 97/684025 | 97/684025 | Akorn, Inc. |
| IC-GREEN | Germany | 39729824.2 | 39729824 | Akorn, Inc. |
| IC-GREEN | Italy | 362017000074996 | 362017000074996 | Akorn, Inc. |
| IC-GREEN | Switzerland | 4701/1997 | 447511 | Akorn, Inc. |
| IC-GREEN | USA | 75315149 | 2,189,196 | Akorn, Inc. |
| INAPSINE | USA | 72190096 | 783,911 | Akorn, Inc. |
| INDIGO CARMINE | USA | 75825569 | 2,389,845 | Akorn, Inc. |
| HYCILIA | Argentina | 3011174 | 2442900 | Inspire Pharmaceuticals, LLC |
| INSPIRE | USA | 76308782 | 2,578,523 | Inspire Pharmaceuticals, LLC |
| INSPIRE (& design) | USA | 76309035 | 2,578,526 | Inspire Pharmaceuticals, LLC |
| JEFFREY P. GILBARD, MD | USA | 85121025 | 4,556,180 | Advanced Vision Research, LLC |
| MAGINEX | Canada | 1083318 | TMA641833 | Hi-Tech Pharmaceutical Co., LLC |
| MAGINEX | USA | 76052135 | 2,541,622 | Hi-Tech Pharmaceutical Co., LLC |
| MAG-OX 400 | USA | 75576028 | 2,633,768 | Hi-Tech Pharmaceutical Co., LLC |
| MASTER OF MAGNESIUM | USA | 87007233 | 5,355,853 | Hi-Tech Pharmaceutical Co., LLC |
| MULTI-BETIC | USA | 86210334 | 4,613,666 | Hi-Tech Pharmaceutical Co., LLC |

| Title | Country | Application No. | Registration No. | Assignor |
|---|-----------|-----------------|------------------|---------------------------------|
| MYOCHRYSSINE | USA | 76178246 | 2,509,820 | Akorn, Inc. |
| MYORISAN | Canada | 1809727 | TMA1031869 | VersaPharm LLC |
| MYORISAN | USA | 85071559 | 4,199,023 | VersaPharm LLC |
| NEMBUTAL | Canada | 0181445 | UCA17215 | Oak Pharmaceuticals, LLC |
| NEMBUTAL | USA | 71308321 | 285,003 | Oak Pharmaceuticals, LLC |
| OSMO-CORRECTION | USA | 85967253 | 4,837,201 | Advanced Vision Research, LLC |
| PAREMYD | USA | 75839701 | 2,775,998 | Akorn, Inc. |
| PHARMACEUTICAL GRADE (& design) | USA | 78329276 | 3,272,765 | Hi-Tech Pharmaceutical Co., LLC |
| RESTORES EYES NATURAL BALANCE | USA | 85967251 | 4,846,473 | Advanced Vision Research, LLC |
| SINUS BUSTER | Canada | 1378181 | TMA733034 | Hi-Tech Pharmaceutical Co., LLC |
| SINUS BUSTER | USA | 78862364 | 3,194,160 | Hi-Tech Pharmaceutical Co., LLC |
| SINUS BUSTER ALL NATURAL NASAL SPRAY | USA | 78850704 | 3,503,088 | Hi-Tech Pharmaceutical Co., LLC |
| SINUS GENIE | Canada | 1378171 | TMA732672 | Hi-Tech Pharmaceutical Co., LLC |
| STERILID | Australia | 1064550 | 1064550 | Advanced Vision Research, LLC |
| STERILID | EU | 004549721 | 004549721 | Advanced Vision Research, LLC |
| STERILID | India | 1376561 | 1376561 | Advanced Vision Research, LLC |
| STERILID | Mexico | 731418 | 907,931 | Advanced Vision Research, LLC |
| STERILID | USA | 78459733 | 3,140,041 | Advanced Vision Research, LLC |
| T TAYLOR PHARMACEUTICALS AN AKORN COMPANY | USA | 75572570 | 2,340,300 | Akorn, Inc. |
| TEARS RENEWED | USA | 75829829 | 2,429,584 | Akorn, Inc. |
| THERA LID | Canada | 1387723 | TMA766,079 | Advanced Vision Research, LLC |
| THERA TEARS | EU | 002996155 | 002996155 | Advanced Vision Research, LLC |

| Title | Country | Application No. | Registration No. | Assignor |
|------------------------|------------------------|-----------------|------------------|-------------------------------|
| THERA TEARS | Mexico | 731417 | 902036 | Advanced Vision Research, LLC |
| THERA TEARS | USA | 88457133 | 5,943,133 | Advanced Vision Research, LLC |
| THERA TEARS | USA | 74615598 | 2,041,112 | Advanced Vision Research, LLC |
| THERAPY FOR YOUR EYES | USA | 86260607 | 4,843,058 | Advanced Vision Research, LLC |
| THERATEARS EXTRA | USA | 87049747 | 5,586,699 | Advanced Vision Research, LLC |
| THERATEARS | Australia | 730182 | 730182 | Advanced Vision Research, LLC |
| THERATEARS | Canada | 1085366 | TMA573256 | Advanced Vision Research, LLC |
| THERATEARS | Canada | 1153395 | TMA641310 | Advanced Vision Research, LLC |
| THERATEARS | EU | 002153476 | 002153476 | Advanced Vision Research, LLC |
| THERATEARS | Guatemala | 2014000962 | 201476 | Advanced Vision Research, LLC |
| THERATEARS | India | 1376560 | 1376560 | Advanced Vision Research, LLC |
| THERATEARS | International Register | 1197342 | 1197342 | Advanced Vision Research, LLC |
| THERATEARS | Lebanon | N/A | 155229 | Advanced Vision Research, LLC |
| THERATEARS | New Zealand | 274324 | 274324 | Advanced Vision Research, LLC |
| THERATEARS | USA | 76427523 | 2,770,188 | Advanced Vision Research, LLC |
| THERATEARS STERILID | USA | 78459728 | 3,181,614 | Advanced Vision Research, LLC |
| TOLAZINE | USA | 76548343 | 2,905,937 | Akorn Animal Health, LLC |
| TYPE YOU | Canada | 1728450 | TMA1040395 | Akorn, Inc. |
| TYPE YOU | USA | 86631044 | 5,291,486 | Akorn, Inc. |
| TYPE YOU DIABETIC CARE | Canada | 1776093 | TMA1047727 | Akorn, Inc. |
| TYPE YOU DIABETIC CARE | USA | 86966811 | 5,297,364 | Akorn, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|------------------------------|--------------------|-----------------|------------------|---------------------------------|
| URO-MAG | USA | 72450878 | 974,841 | Hi-Tech Pharmaceutical Co., LLC |
| MYORISAN | Mexico | 1144174 | 1217500 | VersaPharm LLC |
| VERSAPHARM INCORPORATED | USA | 76269614 | 2,588,146 | VersaPharm LLC |
| VERSAPHARM INCORPORATED X | USA | 76269637 | 2,685,550 | VersaPharm LLC |
| AKORN PHARM, INC. | US State/Louisiana | N/A | 658517 | VersaPharm LLC |
| VETAKET | USA | 74266573 | 1,803,032 | Akorn Animal Health, LLC |
| VO SOL | USA | 72081126 | 696,678 | Hi-Tech Pharmaceutical Co., LLC |
| YOBINE | USA | 73815446 | 1,587,410 | Akorn Animal Health, LLC |
| ZOSTRIX | USA | 78660833 | 3,106,587 | Hi-Tech Pharmaceutical Co., LLC |
| ZOSTRIX | USA | 73576274 | 1,423,561 | Hi-Tech Pharmaceutical Co., LLC |
| THERATEARS | Kuwait | N/A | 130439 | Advanced Vision Research, LLC |

EXHIBIT 2

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6871943

| | |
|------------------------------|----------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|-----------------------------|----------------|
| AKORN OPERATING COMPANY LLC | 08/02/2021 |

RECEIVING PARTY DATA

| | |
|--------------------------|-----------------------|
| Name: | MEDTECH PRODUCTS INC. |
| Street Address: | 660 WHITE PLAINS ROAD |
| Internal Address: | SUITE 250 |
| City: | TARRYTOWN |
| State/Country: | NEW YORK |
| Postal Code: | 10591 |

PROPERTY NUMBERS Total: 15

| Property Type | Number |
|---------------------|----------|
| Application Number: | 16997148 |
| Application Number: | 17211952 |
| Patent Number: | 8231912 |
| Application Number: | 14722252 |
| Patent Number: | 8449928 |
| Patent Number: | 8932653 |
| Patent Number: | 9050288 |
| Patent Number: | 8900643 |
| Patent Number: | 9301988 |
| Patent Number: | 8535736 |
| Application Number: | 62955249 |
| Application Number: | 62991743 |
| Application Number: | 13961453 |
| Application Number: | 14617404 |
| Application Number: | 15674791 |

CORRESPONDENCE DATA

Fax Number: (312)207-6400

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

PATENT

Phone: 2125494195
Email: gbenoy@reedsmith.com
Correspondent Name: PETER A. EMMI
Address Line 1: 599 LEXINGTON AVENUE, 22ND FLOOR
Address Line 2: REED SMITH LLP
Address Line 4: NEW YORK, NEW YORK 10022

| | |
|--------------------------------|-----------------|
| ATTORNEY DOCKET NUMBER: | 330225.00028 |
| NAME OF SUBMITTER: | GWEN M. BENOY |
| SIGNATURE: | /Gwen M. Benoy/ |
| DATE SIGNED: | 08/18/2021 |

Total Attachments: 46

source=IP_Assignment#page1.tif
source=IP_Assignment#page2.tif
source=IP_Assignment#page3.tif
source=IP_Assignment#page4.tif
source=IP_Assignment#page5.tif
source=IP_Assignment#page6.tif
source=IP_Assignment#page7.tif
source=IP_Assignment#page8.tif
source=IP_Assignment#page9.tif
source=IP_Assignment#page10.tif
source=IP_Assignment#page11.tif
source=IP_Assignment#page12.tif
source=IP_Assignment#page13.tif
source=IP_Assignment#page14.tif
source=IP_Assignment#page15.tif
source=IP_Assignment#page16.tif
source=IP_Assignment#page17.tif
source=IP_Assignment#page18.tif
source=IP_Assignment#page19.tif
source=IP_Assignment#page20.tif
source=IP_Assignment#page21.tif
source=IP_Assignment#page22.tif
source=IP_Assignment#page23.tif
source=IP_Assignment#page24.tif
source=IP_Assignment#page25.tif
source=IP_Assignment#page26.tif
source=IP_Assignment#page27.tif
source=IP_Assignment#page28.tif
source=IP_Assignment#page29.tif
source=IP_Assignment#page30.tif
source=IP_Assignment#page31.tif
source=IP_Assignment#page32.tif
source=IP_Assignment#page33.tif
source=IP_Assignment#page34.tif
source=IP_Assignment#page35.tif

source=IP_Assignment#page36.tif
source=IP_Assignment#page37.tif
source=IP_Assignment#page38.tif
source=IP_Assignment#page39.tif
source=IP_Assignment#page40.tif
source=IP_Assignment#page41.tif
source=IP_Assignment#page42.tif
source=IP_Assignment#page43.tif
source=IP_Assignment#page44.tif
source=IP_Assignment#page45.tif
source=IP_Assignment#page46.tif